Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

394 IV. SPECIAL POPULATIONSPassik, S. D., Kirsh, K. L., & Portenoy, R. K. (2002). Substance abuse issues in palliativecare. In A. Berger, R. K. Portenoy, & D. E. Weissman (Eds.), Principles and practiceof palliative care and supportive oncology (pp. 593–603). Philadelphia: Lippincott/Williams & Wilkins.Passik, S. D., & Portenoy, R. K. (1998). Substance abuse disorders. In J. C. Holland(Ed.), Psycho-oncology (pp. 576–586). New York: Oxford University Press.Perry, S., & Heidrich, G. (1982). Management of pain during débridement: A survey ofU.S. burn units. Pain, 13, 267–280.Peterson, G. M., Randall, C. T. C., & Paterson, J. (1990). Plasma levels of morphineand morphine glucuronides in the treatment of cancer pain: Relationship to renalfunction and route of administration. Eur J Clin Pharmacol, 38, 121–124.Plummer, J. L., Cherry, D. A., Cousins, M. J., Gourlay, G. K., Onley, M. M., & Evans,K. H. (1991). Long-term spinal administration of morphine in cancer and noncancerpain: A retrospective study. Pain, 44, 215–220.Plummer, J. L., Gourlay, G. K., Cherry, D. A., & Cousins, M. J. (1988). Estimation ofmethadone clearance: Application in the management of cancer pain. Pain, 33,313–322.Portenoy, R. K. (1994). Opioid tolerance and efficacy: Basic research and clinical observations.In G. Gebhardt, D. Hammond, T. Jensen (Eds.), Proceedings of the VIIWorld Congress on Pain: Progress in pain research management (Vol. 2, pp. 595–619).Seattle: IASP Press.Portenoy, R. K., & Lesage, P. (1999). Management of cancer pain. Lancet, 353, 1695–1700.Portenoy, R. K., Payne, D., & Jacobsen, P. (1999). Breakthrough pain: Characteristicsand impact in patients with cancer pain. Pain, 81, 129–134.Redmond, D. E., & Krystal, J. H. (1984). Multiple mechanisms of withdrawal fromopioid drugs. Ann Rev Neurosci, 7, 443–478.Regier, D. A., Myers, J. K., Kramer, M., Robins, L. N., Blazer, D. G., Hough, R. L., et al.(1984). The NIMH Epidemiologic Catchment Area program: Historical context,major objectives, and study population characteristics. Arch Gen Psychiatry, 41,934–941.Rinaldi, R. C., Steindler, E. M., Wilford, B. B., & Goodwin, D. (1988). Clarificationand standardization of substance abuse terminology. JAMA, 259, 555–557.Rock, P. E. (Ed.). (1977). Drugs and politics. New Brunswick, NJ: Transaction.Rosenblum, A., Joseph, H., Fong, C., Kipnis, S., Cleeland, C., & Portenoy, R. K.(2003). Prevalence and characteristics of chronic pain among chemically dependentpatients in methadone maintenance and residential treatment facilities.JAMA, 289, 2370–2378.Savage, S. R., Joranson, D. E., Covington, E. C., Schnoll, S. H., Heit, H. A., & Gilson,A. M. (2003). Definitions related to the medical use of opioids: Evolution towardsuniversal agreement. J Pain Symptom Manage, 26, 655–667.Sjogren, P. (1997). Clinical implications of morphine metabolites. In R. K. Portenoy &E. B. Bruera (Eds.), Topics in palliative care (Vol. 1, pp. 163–175). New York:Oxford University Press.Smith, T. J., Staats, P. S., Deer, T., Stearns, L. J., Rauck, R. L., Boortz-Marx, R. L., et al.(2002). Randomized clinical trial of an implantable drug delivery system compared